Exp Cell Res. 2011 May 15;317(9):1255-60. doi: 10.1016/j.yexcr.2011.03.010. Epub 2011 Mar 16.

Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab.

Source

Micromet, Inc, 6707 Democracy Blvd, Bethesda, MD 20817, USA. dirk.nagorsen@micromet.com

Abstract

Severe side effects and few long-term remissions frequently limit the treatment of advanced malignant diseases. Bispecific antibodies are currently emerging as a new option for the treatment of malignant diseases, which can potentially engage all cytotoxic T cells of a patient for tumor cell lysis. Blinatumomab, a bispecific single-chain BiTE antibody construct with dual specificity for CD19 and CD3, is a front runner of this antibody class. We here summarize the current state of development of blinatumomab for the treatment of patients with B-cell non-Hodgkin's lymphoma (NHL) and B-precursor acute lymphocytic leukemia (ALL). High response rates and durable remissions are observed in first clinical trials, indicating that T cells can be potently redirected for efficient and lasting elimination of malignant cells.

PMID:: 21419116; [PubMed - indexed for MEDLINE]

Publication Types, MeSH Terms, Substances

Publication Types

Review

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Labome Researcher Resource - ExactAntigen/Labome

Medical

Supplemental Content

Save items

Related citations in PubMed

Review Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab. [Leuk Lymphoma. 2009]
Review Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab.
Nagorsen D, Bargou R, Ruttinger D, Kufer P, Baeuerle PA, Zugmaier G. Leuk Lymphoma. 2009 Jun; 50(6):886-91.
Review Blinatumomab: a historical perspective. [Pharmacol Ther. 2012]
Review Blinatumomab: a historical perspective.
Nagorsen D, Kufer P, Baeuerle PA, Bargou R. Pharmacol Ther. 2012 Dec; 136(3):334-42. Epub 2012 Aug 24.
Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. [Science. 2008]
Tumor regression in cancer patients by very low doses of a T cell-engaging antibody.
Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S, Noppeney R, Viardot A, Hess G, Schuler M, et al. Science. 2008 Aug 15; 321(5891):974-7.
A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. [Blood. 2000]
A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes.
Löffler A, Kufer P, Lutterbüse R, Zettl F, Daniel PT, Schwenkenbecher JM, Riethmüller G, Dörken B, Bargou RC. Blood. 2000 Mar 15; 95(6):2098-103.
Clinical experience with CD3 x CD19 bispecific antibodies in patients with B cell malignancies. [J Hematother. 1995]
Clinical experience with CD3 x CD19 bispecific antibodies in patients with B cell malignancies.
De Gast GC, Van Houten AA, Haagen IA, Klein S, De Weger RA, Van Dijk A, Phillips J, Clark M, Bast BJ. J Hematother. 1995 Oct; 4(5):433-7.

See reviews... See all...

Cited by 7 PubMed Central articles

Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia. [Clin Pharmacol. 2013]
Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia.
Portell CA, Wenzell CM, Advani AS. Clin Pharmacol. 2013; 5(Suppl 1):5-11. Epub 2013 Apr 12.
Trial watch: Monoclonal antibodies in cancer therapy. [Oncoimmunology. 2013]
Trial watch: Monoclonal antibodies in cancer therapy.
Vacchelli E, Eggermont A, Galon J, Sautès-Fridman C, Zitvogel L, Kroemer G, Galluzzi L. Oncoimmunology. 2013 Jan 1; 2(1):e22789.
A sensitivity scale for targeting T cells with chimeric antigen receptors (CARs) and bispecific T-cell Engagers (BiTEs). [Oncoimmunology. 2012]
A sensitivity scale for targeting T cells with chimeric antigen receptors (CARs) and bispecific T-cell Engagers (BiTEs).
Stone JD, Aggen DH, Schietinger A, Schreiber H, Kranz DM. Oncoimmunology. 2012 Sep 1; 1(6):863-873.

See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
MedGen
Related information in MedGen
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumom...
Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab.
Exp Cell Res. 2011 May 15 ;317(9):1255-60. doi: 10.1016/j.yexcr.2011.03.010. Epub 2011 Mar 16 .

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to: